Home / 9926.HK : HKSE

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does 9926.HK make money? Does 9926.HK have pricing power? What's the Earnings Whisper? Will 9926.HK profit more as the business scales? What is 9926.HK's management track record? Is 9926.HK's current price justified?

Akeso, Inc.

HKD 95.25 -$18.05 (-15.93%)

HKSE · 15 Sep 2026 08:08 UTC

Previous Close

HKD 95.7

Day Range

HKD 93.6HKD 96.4

Year Range

HKD 80.2HKD 156

Market Cap

87.63B

AVG Volume

13.19M

Trailing/Forward PE

-78.21/78.11

PEG ratio

0.11

Dividend Yield

Next Earnings Date

2027-03-31

Primary Exchange

Hong Kong Stock Exchange

Revenue (CNY)

9926.HK Revenue (CNY) by quarter
Period	Revenue (CNY)
26 Q2	1.78B
25 Q4	1.62B
25 Q2	1.41B
24 Q4	1.1B
24 Q2	1.02B
23 Q4	849.39M
23 Q2	3.68B
22 Q4	674.52M
22 Q2	163.13M
21 Q4	97.03M

Net Income (CNY)

9926.HK Net Income (CNY) by quarter
Period	Net Income (CNY)
26 Q2	-418.36M
25 Q4	-533.89M
25 Q2	-570.08M
24 Q4	-275.93M
24 Q2	-238.59M
23 Q4	-496.75M
23 Q2	2.53B
22 Q4	-537.96M
22 Q2	-630.43M
21 Q4	-650.03M

Operating Income (CNY)

9926.HK Operating Income (CNY) by quarter
Period	Operating Income (CNY)
26 Q2	-278.51M
25 Q4	-481.07M
25 Q2	-414.46M
24 Q4	-285.79M
24 Q2	-272.43M
23 Q4	-436.75M
23 Q2	2.32B
22 Q4	-790.52M
22 Q2	-747.05M
21 Q4	-857.78M

EBITDA (CNY)

9926.HK EBITDA (CNY) by quarter
Period	EBITDA (CNY)
26 Q2	-454.59M
25 Q4	-366.64M
25 Q2	-403.49M
24 Q4	-300.53M
24 Q2	-304.46M
23 Q4	-488.05M
23 Q2	2.38B
22 Q4	-738.96M
22 Q2	-706.89M
21 Q4	-824.25M

Cash Flows (CNY)

9926.HK Cash Flows (CNY) by quarter
Period	Cash Flows (CNY)
26 Q2	290.28M
25 Q4	-1.14B
25 Q2	-227.5M
24 Q4	63.68M
24 Q2	-591.29M
23 Q4	-774.39M
23 Q2	2.52B
22 Q4	-1.14B
22 Q2	-877.73M
21 Q4	-1.07B

EPS (CNY)

9926.HK EPS (CNY) by quarter
Period	EPS (CNY)
26 Q2	-0.46
25 Q4	-0.58
25 Q2	-0.64
24 Q4	-0.32
24 Q2	-0.28
23 Q4	-0.59
23 Q2	3.01
22 Q4	-0.64
22 Q2	-0.77
21 Q4	-0.8

Expenses (CNY)

9926.HK Expenses (CNY) by quarter
Period	Expenses (CNY)
26 Q2	1.73B
25 Q4	2.03B
25 Q2	2.02B
24 Q4	938.31M
24 Q2	1.45B
23 Q4	1.6B
23 Q2	1.47B
22 Q4	1.72B
22 Q2	1.13B
21 Q4	1.32B

Cash & Debt (CNY)

9926.HK Cash & Debt (CNY) by quarter
Period	Cash & Debt (CNY)
26 Q2	9.16B
25 Q4	9.18B
25 Q2	7.68B
24 Q4	7.32B
24 Q2	2.49B
23 Q4	4.04B
23 Q2	5.82B
22 Q4	2.57B
22 Q2	2.61B
21 Q4	3.23B

Debt ratios

9926.HK Debt ratios by quarter
Period	Debt ratios
26 Q2	2.74
25 Q4	3.36
25 Q2	2.1
24 Q4	-2.61
24 Q2	0.97
23 Q4	-2.36
23 Q2	-27.83
22 Q4	0.17
22 Q2	0.39
21 Q4	0.94

Margins

9926.HK Margins by quarter
Period	Margins
26 Q2	74.24%
25 Q4	78.02%
25 Q2	79.39%
24 Q4	81.63%
24 Q2	91.5%
23 Q4	93.07%
23 Q2	97.86%
22 Q4	88.94%
22 Q2	82.54%
21 Q4	67.44%

Return on Capital

9926.HK Return on Capital by quarter
Period	Return on Capital
26 Q2	-5%
25 Q4	-5.97%
25 Q2	-8.97%
24 Q4	-4.09%
24 Q2	-4.64%
23 Q4	-10.99%
23 Q2	46.34%
22 Q4	-18.8%
22 Q2	-20.2%
21 Q4	-16.2%

Shares Outstanding

9926.HK Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	918.64M
25 Q4	911.09M
25 Q2	890.75M
24 Q4	857.28M
24 Q2	844.77M
23 Q4	836.79M
23 Q2	837.55M
22 Q4	831.13M
22 Q2	814.07M
21 Q4	816.96M

Book Value Per Share (CNY)

9926.HK Book Value Per Share (CNY) by quarter
Period	Book Value Per Share (CNY)
26 Q2	9.1
25 Q4	9.82
25 Q2	7.14
24 Q4	7.88
24 Q2	6.09
23 Q4	5.4
23 Q2	6.51
22 Q4	3.44
22 Q2	3.83
21 Q4	4.91

Total Assets (CNY)

9926.HK Total Assets (CNY) by quarter
Period	Total Assets (CNY)
26 Q2	16.22B
25 Q4	16.01B
25 Q2	13.29B
24 Q4	12.75B
24 Q2	10.46B
23 Q4	9.18B
23 Q2	9.72B
22 Q4	6.17B
22 Q2	5.84B
21 Q4	5.88B

PE Ratio

9926.HK PE Ratio by quarter
Period	PE Ratio
Sep 25	68.91
Sep 25	67.22
Sep 25	70.27
Sep 25	80.14
Aug 25	80.64
Aug 25	91.86
Aug 25	86.02
Aug 25	83.13
Aug 25	81.33
Jul 25	77.11
Jul 25	72.88
Jul 25	58.54
Jul 25	60.01
Jun 25	47.86
Jun 25	47.16
Jun 25	49.66
Jun 25	42.67
May 25	43.58
May 25	43.17
May 25	43.63
May 25	44.44
May 25	46.65
Apr 25	52.61
Apr 25	44.18
Apr 25	43.78
Apr 25	45.54
Mar 25	47.01
Mar 25	42.64
Mar 25	45.25
Mar 25	45.8
Feb 25	46.1
Feb 25	43.42
Feb 25	37.86
Feb 25	41.01
Jan 25	38.22
Jan 25	39.31
Jan 25	37.55
Jan 25	35.68
Jan 25	37.03
Dec 24	37.7
Dec 24	38.53
Dec 24	40.2
Dec 24	41.13
Nov 24	45.92
Nov 24	45.36
Nov 24	43.1
Nov 24	42.35
Nov 24	42.15
Oct 24	42.98
Oct 24	42.68
Oct 24	39.66
Oct 24	45.37
Sep 24	59.17
Sep 24	57.69
Sep 24	54.56
Sep 24	42.68
Aug 24	43.45
Aug 24	40.82
Aug 24	40.21
Aug 24	39.17
Aug 24	37.48
Jul 24	36.74
Jul 24	36.45
Jul 24	36.33
Jul 24	35.22
Jun 24	34.19
Jun 24	32.27
Jun 24	36.02
Jun 24	36.69
May 24	39.66
May 24	33.42
May 24	43.88
May 24	44.96
May 24	44.19
Apr 24	43.87
Apr 24	39.49
Apr 24	44.48
Apr 24	40.55
Mar 24	51.06
Mar 24	50.5
Mar 24	56.64
Mar 24	51.46
Mar 24	50.88
Feb 24	49.65
Feb 24	47.85
Feb 24	44.54
Feb 24	43.49
Jan 24	45.55
Jan 24	45.21
Jan 24	49.53
Jan 24	47.12
Dec 23	49.99
Dec 23	45.38
Dec 23	49.96
Dec 23	46.98
Dec 23	52.51
Nov 23	50.95
Nov 23	51.31
Nov 23	53.05
Nov 23	49.27

Free Cash Flow Yield

9926.HK Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-2.54%
Sep 26	-2.69%
Sep 26	-2.4%
Aug 26	-2.54%
Aug 26	-2.69%
Aug 26	-2.52%
Aug 26	-2.42%
Jul 26	-2.57%
Jul 26	-2.42%
Jul 26	-2.72%
Jul 26	-2.47%
Jul 26	-2.35%
Jun 26	-2.88%
Jun 26	-2.75%
Jun 26	-2.62%
Jun 26	-2.57%
May 26	-2.04%
May 26	-2.06%
May 26	-1.99%
May 26	-1.79%
Apr 26	-1.76%
Apr 26	-1.81%
Apr 26	-1.58%
Apr 26	-1.72%
Apr 26	-1.68%
Mar 26	-1.54%
Mar 26	-1.69%
Mar 26	-1.77%
Mar 26	-1.82%
Feb 26	-1.83%
Feb 26	-1.78%
Feb 26	-1.85%
Feb 26	-1.92%
Jan 26	-1.75%
Jan 26	-1.65%
Jan 26	-1.59%
Jan 26	-1.5%
Jan 26	-1.69%
Dec 25	-1.69%
Dec 25	-1.62%
Dec 25	-1.52%
Dec 25	-1.52%
Nov 25	-1.54%
Nov 25	-1.76%
Nov 25	-1.58%
Nov 25	-1.67%
Oct 25	-1.65%
Oct 25	-1.62%
Oct 25	-1.53%
Oct 25	-1.46%
Oct 25	-1.34%
Sep 25	1.17%
Sep 25	1.2%
Sep 25	1.15%
Sep 25	1.01%
Aug 25	1%
Aug 25	0.88%
Aug 25	0.94%
Aug 25	0.97%
Aug 25	0.99%
Jul 25	1.05%
Jul 25	1.11%
Jul 25	1.38%
Jul 25	1.34%
Jun 25	1.68%
Jun 25	1.71%
Jun 25	1.62%
Jun 25	1.89%
May 25	1.85%
May 25	1.87%
May 25	1.85%
May 25	1.81%
May 25	1.73%
Apr 25	1.53%
Apr 25	1.83%
Apr 25	1.84%
Apr 25	1.77%
Mar 25	0.03%
Mar 25	0.04%
Mar 25	0.03%
Mar 25	0.03%
Feb 25	0.03%
Feb 25	0.03%
Feb 25	0.04%
Feb 25	0.04%
Jan 25	0.04%
Jan 25	0.04%
Jan 25	0.04%
Jan 25	0.04%
Jan 25	0.04%
Dec 24	0.04%
Dec 24	0.04%
Dec 24	0.04%
Dec 24	0.04%
Nov 24	0.03%
Nov 24	0.03%
Nov 24	0.03%
Nov 24	0.04%
Nov 24	0.04%
Oct 24	0.03%

Price to Sales

9926.HK Price to Sales by quarter
Period	Price to Sales
Sep 26	14.47
Sep 26	13.66
Sep 26	15.32
Aug 26	14.46
Aug 26	13.68
Aug 26	14.58
Aug 26	15.21
Jul 26	14.3
Jul 26	15.19
Jul 26	13.5
Jul 26	14.86
Jul 26	15.65
Jun 26	12.77
Jun 26	13.37
Jun 26	14.04
Jun 26	14.29
May 26	18.03
May 26	17.88
May 26	18.48
May 26	20.58
Apr 26	20.93
Apr 26	20.3
Apr 26	23.24
Apr 26	21.31
Apr 26	21.82
Mar 26	22.66
Mar 26	20.64
Mar 26	19.72
Mar 26	19.22
Feb 26	19.04
Feb 26	19.59
Feb 26	18.91
Feb 26	18.2
Jan 26	19.95
Jan 26	21.14
Jan 26	21.96
Jan 26	23.2
Jan 26	20.66
Dec 25	20.63
Dec 25	21.54
Dec 25	22.92
Dec 25	22.9
Nov 25	22.69
Nov 25	19.85
Nov 25	22.04
Nov 25	20.87
Oct 25	21.1
Oct 25	21.5
Oct 25	22.85
Oct 25	23.84
Oct 25	25.98
Sep 25	15.69
Sep 25	15.3
Sep 25	15.99
Sep 25	18.24
Aug 25	18.36
Aug 25	20.91
Aug 25	19.58
Aug 25	18.92
Aug 25	18.51
Jul 25	17.55
Jul 25	16.59
Jul 25	13.33
Jul 25	13.66
Jun 25	10.9
Jun 25	10.73
Jun 25	11.3
Jun 25	9.71
May 25	9.92
May 25	9.83
May 25	9.93
May 25	10.12
May 25	10.62
Apr 25	11.98
Apr 25	10.06
Apr 25	9.97
Apr 25	10.37
Mar 25	9.45
Mar 25	8.57
Mar 25	9.1
Mar 25	9.21
Feb 25	9.27
Feb 25	8.73
Feb 25	7.61
Feb 25	8.25
Jan 25	7.69
Jan 25	7.9
Jan 25	7.55
Jan 25	7.17
Jan 25	7.45
Dec 24	7.58
Dec 24	7.75
Dec 24	8.08
Dec 24	8.27
Nov 24	9.23
Nov 24	9.12
Nov 24	8.67
Nov 24	8.51
Nov 24	8.47
Oct 24	8.64

EV/EBITDA

9926.HK EV/EBITDA by quarter
Period	EV/EBITDA
Sep 25	78.41
Sep 25	76.43
Sep 25	80.01
Sep 25	91.62
Aug 25	92.21
Aug 25	105.4
Aug 25	98.53
Aug 25	95.14
Aug 25	93.01
Jul 25	88.06
Jul 25	83.08
Jul 25	66.22
Jul 25	67.95
Jun 25	53.67
Jun 25	52.84
Jun 25	55.78
Jun 25	47.57
May 25	48.63
May 25	48.15
May 25	48.69
May 25	49.64
May 25	52.24
Apr 25	59.25
Apr 25	49.33
Apr 25	48.87
Apr 25	50.94
Mar 25	70.29
Mar 25	63.85
Mar 25	67.69
Mar 25	68.51
Feb 25	68.94
Feb 25	65
Feb 25	56.8
Feb 25	61.44
Jan 25	57.33
Jan 25	58.93
Jan 25	56.35
Jan 25	53.59
Jan 25	55.57
Dec 24	56.56
Dec 24	57.79
Dec 24	60.24
Dec 24	61.61
Nov 24	68.67
Nov 24	67.85
Nov 24	64.52
Nov 24	63.41
Nov 24	63.12
Oct 24	64.35
Oct 24	63.91
Oct 24	59.45
Oct 24	67.87
Sep 24	111.59
Sep 24	108.73
Sep 24	102.71
Sep 24	79.84
Aug 24	81.31
Aug 24	76.25
Aug 24	75.07
Aug 24	73.07
Aug 24	69.82
Jul 24	68.39
Jul 24	67.84
Jul 24	67.6
Jul 24	65.46
Jun 24	63.48
Jun 24	59.78
Jun 24	67.01
Jun 24	68.3
May 24	74.01
May 24	62.01
May 24	82.14
May 24	84.21
May 24	82.75
Apr 24	82.13
Apr 24	73.69
Apr 24	83.3
Apr 24	75.72
Mar 24	299.16
Mar 24	295.64
Mar 24	334.91
Mar 24	301.74
Mar 24	298.02
Feb 24	290.18
Feb 24	278.65
Feb 24	257.43
Feb 24	250.68
Jan 24	263.88
Jan 24	261.71
Jan 24	289.38
Jan 24	273.97
Dec 23	292.34
Dec 23	262.84
Dec 23	292.14
Dec 23	273.08
Dec 23	308.5
Nov 23	298.5
Nov 23	300.82
Nov 23	311.92
Nov 23	287.71

Price/Operating Cashflow

9926.HK Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
Sep 25	53.76
Sep 25	52.45
Sep 25	54.82
Sep 25	62.53
Aug 25	62.92
Aug 25	71.67
Aug 25	67.11
Aug 25	64.86
Aug 25	63.45
Jul 25	60.16
Jul 25	56.86
Jul 25	45.67
Jul 25	46.83
Jun 25	37.35
Jun 25	36.79
Jun 25	38.75
Jun 25	33.3
May 25	34
May 25	33.68
May 25	34.04
May 25	34.68
May 25	36.4
Apr 25	41.05
Apr 25	34.47
Apr 25	34.16
Apr 25	35.53
Mar 25	40.26
Mar 25	36.52
Mar 25	38.75
Mar 25	39.23
Feb 25	39.48
Feb 25	37.19
Feb 25	32.42
Feb 25	35.12
Jan 25	32.74
Jan 25	33.66
Jan 25	32.16
Jan 25	30.56
Jan 25	31.71
Dec 24	32.29
Dec 24	33
Dec 24	34.43
Dec 24	35.22
Nov 24	39.33
Nov 24	38.85
Nov 24	36.91
Nov 24	36.27
Nov 24	36.1
Oct 24	36.81
Oct 24	36.56
Oct 24	33.97
Oct 24	38.86
Sep 24	41.46
Sep 24	40.42
Sep 24	38.23
Sep 24	29.9
Aug 24	30.44
Aug 24	28.6
Aug 24	28.17
Aug 24	27.44
Aug 24	26.26
Jul 24	25.74
Jul 24	25.54
Jul 24	25.45
Jul 24	24.67
Jun 24	23.95
Jun 24	22.61
Jun 24	25.24
Jun 24	25.71
May 24	27.78
May 24	23.42
May 24	30.74
May 24	31.5
May 24	30.96
Apr 24	30.74
Apr 24	27.67
Apr 24	31.17
Apr 24	28.41
Mar 24	36.96
Mar 24	36.56
Mar 24	41
Mar 24	37.25
Mar 24	36.83
Feb 24	35.95
Feb 24	34.64
Feb 24	32.24
Feb 24	31.48
Jan 24	32.97
Jan 24	32.73
Jan 24	35.86
Jan 24	34.11
Dec 23	36.19
Dec 23	32.86
Dec 23	36.17
Dec 23	34.01
Dec 23	38.02
Nov 23	36.89
Nov 23	37.15
Nov 23	38.4
Nov 23	35.67

Price to Book

9926.HK Price to Book by quarter
Period	Price to Book
Sep 26	8.33
Sep 26	7.86
Sep 26	8.82
Aug 26	8.33
Aug 26	7.88
Aug 26	8.4
Aug 26	8.76
Jul 26	8.23
Jul 26	8.75
Jul 26	7.77
Jul 26	8.56
Jul 26	9.01
Jun 26	7.35
Jun 26	7.7
Jun 26	8.08
Jun 26	8.23
May 26	10.38
May 26	10.29
May 26	10.64
May 26	11.85
Apr 26	12.05
Apr 26	11.69
Apr 26	13.38
Apr 26	12.27
Apr 26	12.56
Mar 26	15.63
Mar 26	14.24
Mar 26	13.6
Mar 26	13.26
Feb 26	13.13
Feb 26	13.51
Feb 26	13.04
Feb 26	12.56
Jan 26	13.76
Jan 26	14.58
Jan 26	15.15
Jan 26	16
Jan 26	14.25
Dec 25	14.23
Dec 25	14.86
Dec 25	15.81
Dec 25	15.79
Nov 25	15.65
Nov 25	13.69
Nov 25	15.21
Nov 25	14.4
Oct 25	14.55
Oct 25	14.83
Oct 25	15.76
Oct 25	16.44
Oct 25	17.92
Sep 25	15.45
Sep 25	15.07
Sep 25	15.75
Sep 25	17.96
Aug 25	18.07
Aug 25	20.59
Aug 25	19.28
Aug 25	18.63
Aug 25	18.23
Jul 25	17.28
Jul 25	16.34
Jul 25	13.12
Jul 25	13.45
Jun 25	10.73
Jun 25	10.57
Jun 25	11.13
Jun 25	9.57
May 25	9.77
May 25	9.68
May 25	9.78
May 25	9.96
May 25	10.46
Apr 25	11.79
Apr 25	9.9
Apr 25	9.81
Apr 25	10.21
Mar 25	11.45
Mar 25	10.38
Mar 25	11.02
Mar 25	11.15
Feb 25	11.22
Feb 25	10.57
Feb 25	9.22
Feb 25	9.98
Jan 25	9.31
Jan 25	9.57
Jan 25	9.14
Jan 25	8.69
Jan 25	9.01
Dec 24	9.18
Dec 24	9.38
Dec 24	9.79
Dec 24	10.01
Nov 24	11.18
Nov 24	11.04
Nov 24	10.49
Nov 24	10.31
Nov 24	10.26
Oct 24	10.46

No video analysis for this stock yet. Request one from our team.

News: 9926.HK

prnewswire.com · 2 Sep 2026

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that a pre-specified interim analysis of overall survival (OS) in the

prnewswire.com · 20 Jul 2026

Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC

/PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study

AI Analysis

Akeso, Inc.

Video analysis: 9926.HK

News: 9926.HK

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC

Similar companies